Disease Clusters?
Groups of diseases that share a large number of curated genes with each other, computed via label propagation over the shared-gene similarity graph. See also Shared-Gene Disease Pairs for pairwise comparisons.
← Back to all clusters
Cluster 299
6
Diseases
20
Unique genes
0.228
Avg. similarity score
Atypical teratoid rhabdoid tumor
Most-connected disease (4 links)
Disease
Pinned (dragged)
Node size = connections within this cluster · edge thickness = similarity strength · hover an edge for its details ·
click a node to select it and show its pairs below (double-click or Ctrl/⌘-click opens the disease page) ·
drag a node to pin it in place · scroll/pinch to zoom.
Atypical teratoid rhabdoid tumor
Rhabdoid tumor
Schwannomatosis
rhabdoid tumor predisposition syndrome 1
Coffin-siris syndrome
NF2-related schwannomatosis
Member diseases (most connected first ‐ the cluster's core)
| Disease ⇵ | Connections in cluster ⇵ | Significant partners ⇵ | Curated genes ⇵ |
|---|---|---|---|
| Atypical teratoid rhabdoid tumor | 4 | 4 | 1 |
| Rhabdoid tumor | 4 | 4 | 2 |
| Schwannomatosis | 4 | 4 | 3 |
| rhabdoid tumor predisposition syndrome 1 | 4 | 4 | 1 |
| Coffin-siris syndrome | 3 | 3 | 17 |
| NF2-related schwannomatosis | 1 | 1 | 1 |
Top shared genes (genes linked to 2+ member diseases)
| Gene ⇵ | Member diseases ⇵ | Linked diseases |
|---|---|---|
| SMARCB1 | 5 / 6 | Atypical teratoid rhabdoid tumor, Coffin-siris syndrome, Rhabdoid tumor, rhabdoid tumor predisposition syndrome 1 and 1 more |
| NF2 | 2 / 6 | NF2-related schwannomatosis, Schwannomatosis |
What do these columns mean?
- Connections in cluster
- How many other members this disease has a shared-gene link to (the node size in the network above). The most-connected diseases are the cluster's core.
- Significant partners
- How many of those links are statistically significant (FDR q < 0.05).
- Curated genes
- Distinct curated genes linked to that disease in GeDiPNet.
- Member diseases (Top shared genes)
- How many of this cluster's diseases are linked to the gene, out of the cluster's total. Genes shared by many members are the most direct explanation of why they group together.
- Overlap genes (x / y)
- x = genes shared between this cluster and the pathway/GO term; y = that pathway/GO term's total gene count. A higher x relative to y (and to the cluster's own size) means a tighter biological match.
- Cluster gene count
- Total distinct genes across every disease in this cluster -- the "n" used in the significance test below.
- Fold enrichment
- Observed overlap divided by the overlap expected by chance, given the cluster's gene count, the pathway/term's size and the gene universe tested. 5× means five times more shared genes than random. Tells strong hits apart when q-values are all vanishingly small.
- P-value / FDR q-value
- Is this pathway/GO term's overlap with the cluster more than chance? Upper-tail hypergeometric test, Benjamini-Hochberg corrected across every tested pathway/term (prefer the q-value -- it accounts for testing many at once).
- Shared genes (Pairs within this cluster)
- Number of curated genes the two diseases in that row have in common.
- Similarity score (Pairs within this cluster)
- Jaccard-based gene overlap between the two specific diseases in that row -- same metric as the main Shared-Gene Disease Pairs page.
Enriched Pathways (why this cluster is grouped, biologically)
| Pathway ⇵ | Source ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | Reactome | 9 / 38 | 142× | 1.87e-18 | 1.18e-15 ✓ sig. |
| ATP-dependent chromatin remodeling | KEGG | 11 / 117 | 56.5× | 7.24e-18 | 4.05e-15 ✓ sig. |
| RMTs methylate histone arginines | Reactome | 9 / 79 | 68.4× | 2.28e-15 | 8.19e-13 ✓ sig. |
| Hepatocellular carcinoma | KEGG | 9 / 170 | 31.8× | 2.71e-12 | 5.44e-10 ✓ sig. |
| Thermogenesis | KEGG | 9 / 234 | 23.1× | 4.84e-11 | 7.48e-9 ✓ sig. |
| RSK activation | Reactome | 1 / 4 | 150× | 6.65e-3 | 5.28e-2 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | Reactome | 1 / 5 | 120× | 8.30e-3 | 6.10e-2 |
| CREB phosphorylation | Reactome | 1 / 7 | 85.8× | 1.16e-2 | 7.50e-2 |
| Gastrin-CREB signalling pathway via PKC and MAPK | Reactome | 1 / 9 | 66.7× | 1.49e-2 | 8.66e-2 |
| The activation of arylsulfatases | Reactome | 1 / 13 | 46.2× | 2.14e-2 | 1.07e-1 |
| ERK/MAPK targets | Reactome | 1 / 14 | 42.9× | 2.31e-2 | 1.12e-1 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | Reactome | 1 / 20 | 30.0× | 3.28e-2 | 1.36e-1 |
| Chromatin modifying enzymes | Reactome | 1 / 20 | 30.0× | 3.28e-2 | 1.36e-1 |
| RHO GTPases activate PAKs | Reactome | 1 / 23 | 26.1× | 3.76e-2 | 1.46e-1 |
| Hippo signaling pathway - multiple species | KEGG | 1 / 29 | 20.7× | 4.72e-2 | 1.66e-1 |
Enriched GO Terms (Biological Process, a second line of biological evidence)
| GO term ⇵ | GO ID ⇵ | Overlap genes ⇵ | Fold enrichment ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| regulation of G0 to G1 transition | GO:0070316 | 10 / 25 | 374× | 4.20e-25 | 1.35e-21 ✓ sig. |
| regulation of nucleotide-excision repair | GO:2000819 | 10 / 28 | 334× | 1.68e-24 | 4.99e-21 ✓ sig. |
| regulation of mitotic metaphase/anaphase transition | GO:0030071 | 10 / 34 | 275× | 1.68e-23 | 4.55e-20 ✓ sig. |
| positive regulation of myoblast differentiation | GO:0045663 | 10 / 47 | 199× | 6.58e-22 | 1.35e-18 ✓ sig. |
| positive regulation of double-strand break repair | GO:2000781 | 10 / 47 | 199× | 6.58e-22 | 1.35e-18 ✓ sig. |
| positive regulation of cell differentiation | GO:0045597 | 11 / 83 | 124× | 1.08e-21 | 2.15e-18 ✓ sig. |
| regulation of G1/S transition of mitotic cell cycle | GO:2000045 | 10 / 57 | 164× | 5.46e-21 | 1.02e-17 ✓ sig. |
| positive regulation of T cell differentiation | GO:0045582 | 9 / 40 | 210× | 5.91e-20 | 9.57e-17 ✓ sig. |
| nucleosome disassembly | GO:0006337 | 7 / 21 | 311× | 5.67e-17 | 5.76e-14 ✓ sig. |
| chromatin remodeling | GO:0006338 | 12 / 320 | 35.0× | 5.77e-17 | 5.83e-14 ✓ sig. |
| positive regulation of stem cell population maintenance | GO:1902459 | 8 / 47 | 159× | 1.05e-16 | 1.00e-13 ✓ sig. |
| nervous system development | GO:0007399 | 11 / 631 | 16.3× | 7.60e-12 | 2.86e-9 ✓ sig. |
| chromatin organization | GO:0006325 | 10 / 449 | 20.8× | 8.65e-12 | 3.22e-9 ✓ sig. |
| positive regulation of DNA-templated transcription | GO:0045893 | 11 / 778 | 13.2× | 7.24e-11 | 2.14e-8 ✓ sig. |
| transcription initiation-coupled chromatin remodeling | GO:0045815 | 5 / 41 | 114× | 5.98e-10 | 1.43e-7 ✓ sig. |
Pairs within this cluster, by significance
| Disease A ⇵ | Disease B ⇵ | Similarity score ⇵ | Shared genes ⇵ | P-value ⇵ | FDR q-value ⇵ |
|---|---|---|---|---|---|
| Atypical teratoid rhabdoid tumor | rhabdoid tumor predisposition syndrome 1 | 0.500 | 1 | 6.49e-5 | 2.34e-4 ✓ sig. |
| Atypical teratoid rhabdoid tumor | Rhabdoid tumor | 0.333 | 1 | 1.30e-4 | 3.90e-4 ✓ sig. |
| Rhabdoid tumor | rhabdoid tumor predisposition syndrome 1 | 0.333 | 1 | 1.30e-4 | 3.90e-4 ✓ sig. |
| Atypical teratoid rhabdoid tumor | Schwannomatosis | 0.250 | 1 | 1.95e-4 | 5.28e-4 ✓ sig. |
| NF2-related schwannomatosis | Schwannomatosis | 0.250 | 1 | 1.95e-4 | 5.28e-4 ✓ sig. |
| rhabdoid tumor predisposition syndrome 1 | Schwannomatosis | 0.250 | 1 | 1.95e-4 | 5.28e-4 ✓ sig. |
| Rhabdoid tumor | Schwannomatosis | 0.200 | 1 | 3.90e-4 | 8.52e-4 ✓ sig. |
| Atypical teratoid rhabdoid tumor | Coffin-siris syndrome | 0.056 | 1 | 1.10e-3 | 1.81e-3 ✓ sig. |
| Coffin-siris syndrome | rhabdoid tumor predisposition syndrome 1 | 0.056 | 1 | 1.10e-3 | 1.81e-3 ✓ sig. |
| Coffin-siris syndrome | Rhabdoid tumor | 0.053 | 1 | 2.21e-3 | 3.10e-3 ✓ sig. |